PRO72ARG (RS1042522) XORAZM VILOYATIDA MYELOPROLIFERATIV NEOPLAZALAR RIVOJLANISH BILAN TP53 GENI POLIMORFIZMASI
Abstrakt
Maqsad: TP53 genining Pro72Arg (rs1042522) polimorfizmining allelik va genotipik variantlarining mieloproliferativ neoplaziyalar (MPN) rivojlanishiga ta'sirini baholash. Materiallar va usullar: 110 nafar klinik va genetika jihatidan tasdiqlangan Рh–musbat va Рh–manfiy MPN holatlari bo'lgan bemorlarda Pro72Arg (rs1042522) polimorfizmining TP53 geni tomonidan MPN rivojlanishiga va klinik kechishining prognoziga ta'sirini o‘rganish ishlari olib borildi. Ulardan 34 tasi (XML – 26, IP – 7, IT–1) Xorazm viloyatining ekologik jihatdan noqulay hududlarida yashagan (I–guruh) va 76 tasi (XML – 40, IP – 24, IT – 10, PMF – 2) viloyatning nisbatan qulay hududlarida yashagan (II–guruh). Boshqa guruh sifatida 105 nafar sog‘lom, yaqin qarindosh bo‘lmagan o‘zbekistonliklar DNK namunalaridan foydalanildi. Natijalar: Olingan ma'lumotlarga ko‘ra, Pro alleli kasalliklarning rivojlanish ehtimoli bilan bog‘liq bo‘lib, kontrol guruhidagi yuqori Arg alleli tez-tezligi uning himoya ta'sirini ko‘rsatadi (χ² = 12,4; p = 0,01). Xorazm viloyatining noqulay hududlarida Pro/Pro genotipi sezilarli darajada keng tarqalgan (χ2=5,6; р=0,03; RR=3,6; 95%CI:1,05-12,38;) va MPN rivojlanish xavfini 2 martadan ortiq oshiradi (OR=4,2; 95%CI:1,27-13,57). Pro/Arg genotipi (χ² = 5,9; p = 0,03) kasalliklar rivojlanishi bilan sezilarli bog‘liq bo‘lib, MPN rivojlanish xavfini 2 martadan ortiq oshiradi (OR = 2,1; 95% CI: 1,15-3,77). Arg/Arg genotipi (χ² = 11,1; p = 0,01) esa, aksincha, himoya ta'siri bilan bog‘liq bo‘lib, uning kontrol guruhida yuqori tez-tezligi kasallikning rivojlanish xavfini kamaytiruvchi omil sifatida tasdiqlanadi.
Mualliflar haqida
Adabiyotlar ro'yxati
Schulz E, Sill H. The TP53 Pro72Arg SNP in de novo acute myeloid leukemia. Haematologica. 2017 May;102(5): e214-e215. doi: 10.3324/haematol.2017.165019. PMID: 28458254; PMCID: PMC5477628.
Mohammad Salman Akhtar, Raed A. Alharbi, Genetic association of TP53 Pro72Arg polymorphism (rs1042522) in Leukemia: An updated meta-analysis of 10 case-control studies, Human Gene, Volume 34, 2022, 201130, ISSN 2773-0441, https://doi.org/10.1016/j.humgen.2022.201130.
Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, Foran J, Palmer J, Badar T, Patnaik MM, Reichard KK, He R, Zepeda Mendoza CJ, Shah M, Orazi A, Arber DA, Pardanani A, Vannucchi AM, Hiwase D, Gangat N, Guglielmelli P. TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Jan 28. doi: 10.1002/ajh.27609. Epub ahead of print. PMID: 39873146.
Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017 Jul 13;36(28):3943-3956. doi: 10.1038/onc.2016.502. Epub 2017 Mar 13. PMID: 28288132; PMCID: PMC5511239.
Xiang Zhou, Qian Hao, Hua Lu, Mutant p53 in cancer therapy—the barrier or the path, Journal of Molecular Cell Biology, Volume 11, Issue 4, April 2019, Pages 293–305, https://doi.org/10.1093/jmcb/mjy072
Yi K, Yang L, Lan Z, Xi M. The Association Between p53 Codon 72 Polymorphism and Endometrial Cancer Risk: A System Review and Meta-analysis. Int J Gynecol Cancer. 2016 Jul;26(6):1121-8. doi: 10.1097/IGC.0000000000000725. PMID: 27327151.
Garde-García H, Redondo-González E, Maestro-de Las Casas M, Fernández-Pérez C, Moreno-Sierra J. Biomarkers and intermediate-high risk non-muscle invasive bladder cancer: a multivariate analysis of three different cellular pathways with pronostic implications. Clin Transl Oncol. 2021 Apr;23(4):840-845. doi: 10.1007/s12094-020-02476-7. Epub 2020 Aug 24. PMID: 32839927.
Roshani D, Abdolahi A, Rahmati S. Association of p53 codon 72 Arg>Pro polymorphism and risk of cancer in Iranian population: A systematic review and meta-analysis. Med J Islam Repub Iran. 2017 Dec 27;31:136. doi: 10.14196/mjiri.31.136. PMID: 29951436; PMCID: PMC6014797.
Saima Saleem, et al. P53 (Pro72Arg) polymorphism associated with the risk of oral squamous cell carcinoma in gutka, niswar and manpuri addicted patients of Pakistan, Oral Oncology, Volume 49, Issue 8, 2013, Pages 818-823, ISSN 1368-8375, https://doi.org/10.1016/j.oraloncology.2013.04.004.
Drokow EK, Chen Y, Waqas Ahmed HA, Oppong TB, Akpabla GS, Pei Y, Kumah MA, Neku EA, Sun K. The relationship between leukemia and TP53 gene codon Arg72Pro polymorphism: analysis in a multi-ethnic population. Future Oncol. 2020 May;16(14):923-937. doi: 10.2217/fon-2019-0792. Epub 2020 Apr 17. PMID: 32301350.
Diakite, B., Kassogue, Y., Dolo, G. et al. p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies. BMC Med Genet 21, 206 (2020). https://doi.org/10.1186/s12881-020-01133-8
Shen, CC., Cheng, WY., Lee, CH. et al. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment. BMC Cancer 20, 709 (2020). https://doi.org/10.1186/s12885-020-07210-8
Ahmed, S., Safwat, G., Moneer, M.M. et al. Prevalence of TP53 gene Pro72Arg (rs1042522) single nucleotide polymorphism among Egyptian breast cancer patients. Egypt J Med Hum Genet 24, 24 (2023). https://doi.org/10.1186/s43042-023-00405-1
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.